ArcelorMittal S.A. (MT) ended last trading session with a change of -0.99 percent. It trades at an average volume of 17.54M shares versus 28.47M shares recorded at the end of last trading session. The share price of $7.03 is at a distance of 139.93 percent from its 52-week low and down -3.96 percent versus its peak. The company has a market cap of $21.41B and currently has 3.05B shares outstanding. The share price is currently 6.27 percent versus its SMA20, 12.63 percent versus its SMA50, and 32.08 percent versus its SMA200. The stock has a weekly performance of 7.66 percent and is 66.59 percent year-to-date as of the recent close.

November 8, 2016 — ArcelorMittal S.A. (MT) is expanding its global portfolio of automotive steels by introducing a new generation of advanced high strength steels (AHSS). These innovative steels include the launch of new press hardenable steels (PHS) Ductibor® 1000 and Usibor® 2000 – both of which are already available for OEM qualification testing in Europe – and martensitic steels MartINsite® M1700 and M2000. The company is also preparing to expand its family of third generation advanced high strength steel (3G AHSS), which currently includes Fortiform® 1050 in Europe, starting in 2017. Together, these new steel grades will help automakers further reduce body-in-white weight to improve fuel economy without compromising vehicle safety or performance.

AstraZeneca PLC (AZN) recently recorded 1.08 percent change and currently at $27.98 is 5.13 percent away from its 52-week low and down -19.08 percent versus its peak. It has a past 5-day performance of 1.16 percent and trades at an average volume of 5.24M shares. The stock has a 1-month performance of -9.27 percent and is -13.78 percent year-to-date as of the recent close. There were about 2.54B shares outstanding which made its market cap $71.01B. The share price is currently -4.2 percent versus its SMA20, -10.99 percent versus its SMA50, and -7.03 percent versus its SMA200.

November 11, 2016 — Results from the international, multicenter ChildHood Asthma Safety and Efficacy (CHASE) 3 Phase III study showed that SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms significantly improved lung function in pediatric patients between 6 to <12 years of age with asthma versus budesonide 80 micrograms, demonstrating its appropriateness as step-up therapy in this patient population.

The CHASE 3 Phase III study evaluated the efficacy and safety of budesonide/formoterol in a pressurized metered dose inhaler (pMDI) 80/2.25 micrograms, and SYMBICORT pMDI 80/4.5 micrograms, compared with budesonide pMDI 80 micrograms in children with asthma, ages 6 to <12 years, who were given two inhalations twice a day for 12 weeks. The children had previously received either medium-dose inhaled corticosteroid (ICS) or ICS/ long-acting beta2-adrenergic agonists (LABA). The primary efficacy endpoint was change from baseline pre-dose (randomization) to 1-hour post-dose forced expiratory volume in one second (FEV1) at week 12.

AstraZeneca PLC (AZN) conducted the CHASE 3 study after the US Food and Drug Administration (FDA) requested additional data on budesonide and formoterol, specifically regarding the impact of different doses, in pediatric asthma patients between 6 to <12 years of age.